Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 128

1.

Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.

Fink SP, Dawson DM, Zhang Y, Kresak A, Lawrence EG, Yang P, Chen Y, Barnholtz-Sloan JS, Willis JE, Kopelovich L, Markowitz SD.

Carcinogenesis. 2015 Feb;36(2):291-8. doi: 10.1093/carcin/bgu241. Epub 2014 Dec 10.

PMID:
25503930
2.

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.

Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, Saltz LB, Mayer RJ, Benson AB 3rd, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Venook AP, Ogino S, Giovannucci EL, Fuchs CS.

J Natl Cancer Inst. 2014 Nov 27;107(1):345. doi: 10.1093/jnci/dju345. Print 2015 Jan.

PMID:
25432409
3.

Usefulness of selective COX-2 inhibitors as therapeutic agents against canine mammary tumors.

Saito T, Tamura D, Asano R.

Oncol Rep. 2014 Apr;31(4):1637-44. doi: 10.3892/or.2014.3010. Epub 2014 Feb 4.

PMID:
24503782
4.

The discovery and development of cyclooxygenase-2 inhibitors as potential anticancer therapies.

Vosooghi M, Amini M.

Expert Opin Drug Discov. 2014 Mar;9(3):255-67. doi: 10.1517/17460441.2014.883377. Epub 2014 Feb 3. Review.

PMID:
24483845
5.

Pharmacological and dietary prevention for colorectal cancer.

Nolfo F, Rametta S, Marventano S, Grosso G, Mistretta A, Drago F, Gangi S, Basile F, Biondi A.

BMC Surg. 2013;13 Suppl 2:S16. doi: 10.1186/1471-2482-13-S2-S16. Epub 2013 Oct 8. Review.

6.

Aspirin therapy for colorectal cancer with PIK3CA mutation: simply complex!

Fuchs CS, Ogino S.

J Clin Oncol. 2013 Dec 1;31(34):4358-61. doi: 10.1200/JCO.2013.52.0080. Epub 2013 Oct 28. No abstract available.

7.

Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.

Domingo E, Church DN, Sieber O, Ramamoorthy R, Yanagisawa Y, Johnstone E, Davidson B, Kerr DJ, Tomlinson IP, Midgley R.

J Clin Oncol. 2013 Dec 1;31(34):4297-305. doi: 10.1200/JCO.2013.50.0322. Epub 2013 Sep 23.

8.

Aspirin, PIK3CA mutation, and colorectal-cancer survival.

Sahin IH, Garrett C.

N Engl J Med. 2013 Jan 17;368(3):289. doi: 10.1056/NEJMc1214189#SA2. No abstract available.

PMID:
23323915
9.

Aspirin, PIK3CA mutation, and colorectal-cancer survival.

Viúdez A, Hernandez I, Vera R.

N Engl J Med. 2013 Jan 17;368(3):289. doi: 10.1056/NEJMc1214189#SA1. No abstract available.

PMID:
23323914
10.

Aspirin, PIK3CA mutation, and colorectal-cancer survival.

Ogino S, Liao X, Chan AT.

N Engl J Med. 2013 Jan 17;368(3):289-90. doi: 10.1056/NEJMc1214189. No abstract available.

11.

Aspirin--from prevention to targeted therapy.

Pasche B.

N Engl J Med. 2012 Oct 25;367(17):1650-1. doi: 10.1056/NEJMe1210322. No abstract available.

PMID:
23094728
12.

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.

Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S.

N Engl J Med. 2012 Oct 25;367(17):1596-606. doi: 10.1056/NEJMoa1207756.

13.

Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention.

Thompson P, Roe DJ, Fales L, Buckmeier J, Wang F, Hamilton SR, Bhattacharyya A, Green S, Hsu CH, Chow HH, Ahnen DJ, Boland CR, Heigh RI, Fay DE, Martinez ME, Jacobs E, Ashbeck EL, Alberts DS, Lance P.

Cancer Prev Res (Phila). 2012 Dec;5(12):1381-93. doi: 10.1158/1940-6207.CAPR-12-0204. Epub 2012 Oct 11.

14.

Cyclooxygenase/lipoxygenase shunting lowers the anti-cancer effect of cyclooxygenase-2 inhibition in colorectal cancer cells.

Ganesh R, Marks DJ, Sales K, Winslet MC, Seifalian AM.

World J Surg Oncol. 2012 Sep 26;10:200. doi: 10.1186/1477-7819-10-200.

15.
16.

Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo.

Rahman M, Selvarajan K, Hasan MR, Chan AP, Jin C, Kim J, Chan SK, Le ND, Kim YB, Tai IT.

Neoplasia. 2012 Jul;14(7):624-33.

17.

COX-2 active agents in the chemoprevention of colorectal cancer.

Kraus S, Naumov I, Arber N.

Recent Results Cancer Res. 2013;191:95-103. doi: 10.1007/978-3-642-30331-9_5. Review.

PMID:
22893201
18.

Coxibs: pharmacology, toxicity and efficacy in cancer clinical trials.

Garcia Rodriguez LA, Cea-Soriano L, Tacconelli S, Patrignani P.

Recent Results Cancer Res. 2013;191:67-93. doi: 10.1007/978-3-642-30331-9_4. Review.

PMID:
22893200
19.

Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention?

Manzano A, Pérez-Segura P.

ScientificWorldJournal. 2012;2012:327341. doi: 10.1100/2012/327341. Epub 2012 Apr 29. Review.

20.

A further piece of the puzzle: positive FOBT, colonoscopy, aspirin and the prevention of colorectal cancer.

Ockenga J.

Digestion. 2012;85(4):276-7. doi: 10.1159/000337072. Epub 2012 Apr 21. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk